Table 1 Clinical paraments of gastric cancer patients underwent HIPEC

Age, year (mean ± SD)

54.84 ± 12.84

Gender

 Male

43 (68%)

 Female

20 (32%)

 BMI, kg/m² (mean ± SD)

22.52 ± 3.57

Ascites

 Yes

15 (24%)

 No

48 (76%)

Ascites volume/mL

0–2000

Peritoneal lavage fluid

 Positive

11 (17%)

 Negative

6 (10%)

 NA

46 (73%)

PCI score

 ≤ 7

50 (79%)

 > 7

13 (21%)

Cytoreductive surgery

 Yes

55 (87%)

 No

8 (13%)

Completeness of cytoreduction score

 0

39 (62%)

 1

4 (6%)

 2

3 (5%)

 3

17 (27%)

The Number of HIPEC

 One

6 (10%)

 Two

8 (13%)

 Three

45 (72%)

 Four

2 (3%)

 Five

1 (2%)

HIPEC administration

 Oxaliplatin + Raltitrexed + Lobaplatin

11 (18%)

 Oxaliplatin + Raltitrexed

1 (2%)

 Lobaplatin

50 (80%)

Oxaliplatin Dose/mg

280–385

Raltitrexed Dose/mg

4–5.5

Lobaplatin Dose/mg

60–350

Neoadjuvant chemotherapy

 Yes

33 (53%)

 No

29 (47%)

Surgery method

 Proximal gastrectomy

2 (3%)

 Total gastrectomy

33 (52%)

 Distal gastrectomy

20 (32%)

 Without gastrectomy

8 (13%)

Laparoscopic surgery

 Yes

45 (72%)

 No

18 (28%)

Intraoperative blood loss/mL

222.5 ± 210.83